Second of two multi-center trial of IMO-2125 as monotherapy and in combination with check-point inhibitors in multiple tumor types.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2016
At a glance
- Drugs IMO 2125 (Primary)
- Indications Tumours
- Focus Therapeutic Use
- 15 Nov 2016 New trial record
- 28 Oct 2016 According to an Idera Pharmaceuticals media release, company plans to initiate this trial in 2017.